Haemonetics (HAE) Stock Forecast & Price Target

Haemonetics is a well-diversified healthcare company with a focus on plasma and hospital products, as well as a presence in the blood center market. Despite some challenges in certain business segments, the company continues to experience overall growth and has a strong financial outlook for the future. Additionally, the company's efforts to improve sales in previously underperforming areas suggests potential for further growth and profitability in the coming years.

Haemonetics is a medical products and solutions provider focusing on blood and plasma component collection, surgical suite, and hospital transfusion services. The company's growth is heavily reliant on robust performance in its plasma and hospital segments, while competition may hinder its blood center segment. Despite a solid fourth quarter performance, the company faces challenges such as a decline in interventional technologies and pressure on gross margin due to the absence of prior year CSL shortfall payment and tariffs. Furthermore, the company's FY/27 guidance for total reported revenue growth of 4-7%, non-GAAP EPS growth in the mid-single digits, and improvement in adjusted operating margin range is seen as a bit light compared to previous forecast, indicating a possible deceleration in growth. Based on these concerns and uncertainties, the stock may underperform in the short to mid-term.